Search

Your search keyword '"Chen, Diana A."' showing total 451 results

Search Constraints

Start Over You searched for: Author "Chen, Diana A." Remove constraint Author: "Chen, Diana A."
451 results on '"Chen, Diana A."'

Search Results

1. Minimum data set for treatment effectiveness in pyoderma gangrenosum (MIDSTEP): an international protocol of an e-Delphi study to develop a clinical physician-driven treatment effectiveness registry on behalf of the UPGRADE initiative

3. Compassionate Flexibility and Self-Discipline: Student Adaptation to Emergency Remote Teaching in an Integrated Engineering Energy Course during COVID-19

4. The “Understanding Pyoderma Gangrenosum, Review and Assessment of Disease Effects (UPGRADE)” Project: a protocol for the development of the core outcome domain set for trials in pyoderma gangrenosum

5. Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection

6. ATS Core Curriculum 2021. Pediatric Pulmonary Medicine: Pulmonary Infections

10. First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC.

11. Clinical Experience with Cranial Nerve Impairment in the Cartitude-1, Cartitude-2 Cohorts a, B and C, and Cartitude-4 Studies of Ciltacabtagene Autoleucel (Cilta-cel)

12. Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma and 1–3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 Cartitude-4 Trial

13. Virus-associated Inflammation Imprints an Inflammatory Profile on Long-lived Monocyte-derived Macrophages in the Human Liver

14. Longitudinal liver sampling in patients with chronic hepatitis B starting antiviral therapy reveals hepatotoxic [CD8.sup.+] T cells

16. Observations of the global epidemiology of COVID-19 from the prepandemic period using web-based surveillance: a cross-sectional analysis

17. Supranormal thymic output up to 2 decades after HIV-1 infection

21. Hepatitis C virus-specific [CD4.sup.+] T cell phenotype and function in different infection outcomes

23. An Improved Measure of Cognitive Salience in Free Listing Tasks: A Marshallese Example

25. A core domain set for pyoderma gangrenosum trial outcomes: an international eDelphi and consensus study from the UPGRADE initiative.

26. OA-45 Pharmacokinetic and correlative analysis of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma in the CARTITUDE-4 trial

27. OA-47 Additional analysis of CARTITUDE-4: Cilta-cel vs standard of care (PVd or DPd) in lenalidomide-refractory patients with multiple myeloma and 1–3 prior lines of therapy

28. S100: FIRST PHASE 3 RESULTS FROM CARTITUDE-4: CILTA-CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA

29. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

31. Immune Dysregulation after Cardiothoracic Surgery and Incidental Thymectomy: Maintenance of Regulatory T Cells despite Impaired Thymopoiesis

33. Combined adaptive optics: optical coherence tomography and adaptive optics: scanning laser ophthalmoscopy system for retinal imaging

35. Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor–T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)

38. The "Who" in Engineering: Sociotechnical Engineering as Memorable and Relevant.

41. The “Understanding Pyoderma Gangrenosum, Review and Assessment of Disease Effects (UPGRADE)” Project: a protocol for the development of the core outcome domain set for trials in pyoderma gangrenosum

42. S1189 Safety and Efficacy of Oral TLR8 Agonist, Selgantolimod, in Viremic Adult Patients With Chronic Hepatitis B

43. Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression

44. MM-567 Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk

45. MM-522 Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Receiving CAR-T Therapy: Phase 3 CARTITUDE-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma

46. Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Receiving CAR-T Therapy: Phase 3 CARTITUDE-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma

47. Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk

49. Tests and classification methods in adaptive designs with applications.

50. Immigrant foodways in Jersey City, NJ.

Catalog

Books, media, physical & digital resources